Total Payments
$186,553
2024 Payments
$16,168
Companies
7
Transactions
231
Medicare Patients
71
Medicare Billing
$7,997
Payment Breakdown by Category
Other$126,780 (68.0%)
Consulting$33,165 (17.8%)
Travel$21,610 (11.6%)
Food & Beverage$4,913 (2.6%)
Education$84.72 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $119,520 | 66 | 64.1% |
| Consulting Fee | $33,165 | 10 | 17.8% |
| Travel and Lodging | $21,610 | 65 | 11.6% |
| Honoraria | $7,260 | 4 | 3.9% |
| Food and Beverage | $4,913 | 76 | 2.6% |
| Education | $84.72 | 10 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $73,817 | 92 | $0 (2024) |
| ViiV Healthcare Company | $59,610 | 51 | $0 (2023) |
| Paratek Pharmaceuticals, Inc. | $38,111 | 53 | $0 (2023) |
| Insmed, Inc. | $6,528 | 10 | $0 (2022) |
| The Medicines Company | $6,177 | 22 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $2,210 | 2 | $0 (2018) |
| COMSORT, Inc | $100.00 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,168 | 15 | Gilead Sciences, Inc. ($16,168) |
| 2023 | $34,026 | 41 | Paratek Pharmaceuticals, Inc. ($16,538) |
| 2022 | $24,161 | 25 | ViiV Healthcare Company ($8,450) |
| 2021 | $24,343 | 27 | Paratek Pharmaceuticals, Inc. ($10,884) |
| 2020 | $22,370 | 12 | ViiV Healthcare Company ($18,760) |
| 2019 | $31,543 | 45 | ViiV Healthcare Company ($17,066) |
| 2018 | $16,198 | 28 | Gilead Sciences, Inc. ($10,476) |
| 2017 | $17,744 | 38 | Gilead Sciences Inc ($10,397) |
All Payment Transactions
231 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $590.00 | General |
| Category: HIV | ||||||
| 09/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $885.00 | General |
| Category: HIV | ||||||
| 08/26/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,950.00 | General |
| Category: HIV | ||||||
| 08/22/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: HIV | ||||||
| 05/17/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $118.55 | General |
| 05/15/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $77.38 | General |
| 04/20/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,750.00 | General |
| Category: HIV | ||||||
| 04/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: HIV | ||||||
| 04/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $49.99 | General |
| Category: HIV | ||||||
| 04/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $20.47 | General |
| Category: HIV | ||||||
| 04/04/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $1,010.08 | General |
| Category: HIV | ||||||
| 04/04/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $312.55 | General |
| Category: HIV | ||||||
| 04/04/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Travel and Lodging | In-kind items and services | $257.00 | General |
| Category: HIV | ||||||
| 02/05/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,950.00 | General |
| Category: HIV | ||||||
| 02/01/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $121.82 | General |
| Category: HIV | ||||||
| 12/15/2023 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $370.00 | General |
| Category: HIV | ||||||
| 11/15/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,150.00 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $798.00 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $445.18 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | In-kind items and services | $335.75 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $115.13 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | Cash or cash equivalent | $34.17 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | Cash or cash equivalent | $33.26 | General |
| Category: ANTIBIOTIC | ||||||
| 11/08/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Travel and Lodging | Cash or cash equivalent | $30.00 | General |
| Category: ANTIBIOTIC | ||||||
| 09/29/2023 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,730.00 | General |
| Category: HIV | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 18 | 41 | $10,540 | $2,365 |
| 2022 | 1 | 18 | 38 | $9,603 | $2,099 |
| 2021 | 1 | 18 | 34 | $8,214 | $2,191 |
| 2020 | 1 | 17 | 27 | $7,425 | $1,343 |
Total Patients
71
Total Services
140
Medicare Billing
$7,997
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 18 | 41 | $10,540 | $2,365 | 22.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 18 | 38 | $9,603 | $2,099 | 21.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 18 | 34 | $8,214 | $2,191 | 26.7% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 17 | 27 | $7,425 | $1,343 | 18.1% |
About Dr. Gregory Anstead, MD
Dr. Gregory Anstead, MD is a Infectious Disease healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144337213.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gregory Anstead, MD has received a total of $186,553 in payments from pharmaceutical and medical device companies, with $16,168 received in 2024. These payments were reported across 231 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($119,520).
As a Medicare-enrolled provider, Anstead has provided services to 71 Medicare beneficiaries, totaling 140 services with total Medicare billing of $7,997. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location San Antonio, TX
- Active Since 08/24/2006
- Last Updated 05/22/2008
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1144337213
Products in Payments
- NUZYRA (Drug) $38,111
- DOVATO (Drug) $35,935
- Biktarvy (Drug) $31,636
- Veklury (Drug) $7,002
- Arikayce (Drug) $6,528
- ORBACTIV (Drug) $6,142
- Genvoya (Drug) $5,718
- TIVICAY (Drug) $4,541
- JULUCA (Drug) $3,400
- NOXAFIL (Drug) $2,210
- ZERBAXA (Drug) $100.00
- MINOCIN IV (Drug) $6.22
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in San Antonio
Dr. Pablo Feuillet, M.d, M.D
Infectious Disease — Payments: $32,815
Infectious Disease $32,815
Luis Cisneros, Md, MD
Infectious Disease — Payments: $20,110
Infectious Disease $20,110
Robert Zajac, Md, MD
Infectious Disease — Payments: $14,649
Infectious Disease $14,649
Dr. David Chee, M.d, M.D
Infectious Disease — Payments: $13,687
Infectious Disease $13,687
Jan Patterson
Infectious Disease — Payments: $13,366
Infectious Disease $13,366
Dr. Gemma Berlanga, M.d, M.D
Infectious Disease — Payments: $9,476
Infectious Disease $9,476